Numerate
Latest round
- Series A
Last raised
- May 2014
Total raised
- $15M
Investors
- 4
About Numerate
Based in California, US, and founded in 2007 by CEO Guido Lanza, Numerate, Inc. operates as a developer of an AI-based drug engineering platform that is used to design and develop small-molecule therapeutics for accelerating immuno-oncology, regenerative medicine, and the treatment of various diseases like Alzheimer’s and metabolic diseases., a portfolio company of Koch Disruptive Technologies, Longevity Vision Holding, Mirae Asset Capital, Atinum Investment, Invus, HBM Partners, Public Sector Pension Investment Board, and Flagship Pioneering, acquired Numerate, Inc. from Foundation Capital, Lanza Tech Ventures, Atlas Venture, Lilly Ventures, and The National Heart, Lung, and Blood Institute. Numerate, Inc. developed a cloud-based AI platform designed for small-molecule drug discovery. This platform enabled data-driven decisions throughout the drug development lifecycle, from hit identification to lead optimization and candidate selection. It was capable of modeling biological systems with limited, noisy, or biased data and featured predictive models for ADME/Tox and protein target interaction. The company focuses on various therapeutic areas such as neurodegeneration, oncology, and cardiovascular disease, supporting both internal programs and strategic external collaborations.
Who invested in Numerate
4 investors across 3 rounds
See all investors in Numerate
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Numerate
Who invested in Numerate?
Numerate has 4 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Numerate raised?
Numerate has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Numerate last raise money?
Numerate's most recent round on record is a Series A, in May 2014.
What does Numerate do?
Based in California, US, and founded in 2007 by CEO Guido Lanza, Numerate, Inc.
Where is Numerate headquartered?
Numerate is headquartered in San Francisco, US.
Which VCs invest in companies like Numerate?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Numerate's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Numerate? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.